文献速递卫生政策与健康促进免疫规划

2025年毒理学会研讨会总结:后新冠时代的疫苗毒理学

Summary of 2025 Society of Toxicology Workshop "Vaccine Toxicology in the Post-COVID Era".
PubMed 文献 · Vaccine · 2026-10-01

本文总结2025年毒理学会年会上CEPI研讨会的报告,聚焦后新冠时代疫苗毒理学研究的监管视角及脂质纳米颗粒、mRNA疫苗和新型佐剂的开发影响,结论认为应基于约35年经验审查和更新疫苗指南文件。

要点

  • 疫苗非临床安全性研究是药物监管毒理学的专业领域,与化学小分子药物要求不同。
  • 新冠大流行推动mRNA疫苗和脂质纳米颗粒等新技术广泛应用及监管审评程序加速。
  • 研讨会结论认为应审查和更新疫苗指南文件,纳入约35年的经验教训。

核心结论

  • 研讨会结论认为应基于约35年的经验审查和更新疫苗指南文件。

研究设计与样本

  • 本文为2025年毒理学会年会上CEPI研讨会的报告总结,非原始研究。
  • 研讨会聚焦后新冠时代疫苗毒理学研究的多个当前方面。

主要发现

  • 疫苗毒理学评估在许多方面与小分子或其他生物药物所需评估不同。
  • 新冠大流行带来mRNA疫苗广泛引入等疫苗技术快速进展。
  • 监管机构审评程序发生变化以加速临床开发。
  • 研讨会内容包括疫苗非临床安全性测试的监管视角及对脂质纳米颗粒、mRNA疫苗和新型佐剂开发的影响。

关键数值与推荐

  • 疫苗毒理学测试自20世纪90年代中期起被要求,始于EMEA疫苗临床前药理和毒理测试指南(CPMP/SWP/465/95)的发布,该指南后于2016年撤回。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nonclinical safety studies to support clinical development and registration of vaccines is a specialized area within pharmaceutical regulatory toxicology. Toxicology testing for vaccines has been required since the mid-1990s, starting with the publication of the European Medicines Evaluation Agency (EMEA) Note for guidance on preclinical pharmacological and toxicological testing of vaccines (CPMP/SWP/465/95), which was later withdrawn in 2016. Toxicological assessment of vaccines is, in many respects, quite distinct from that required for small molecules or other categories of biological drugs. The coronavirus disease-19 (COVID-19) pandemic brought with it rapid advances in vaccine technology, such as the widespread introduction of mRNA vaccines, as well as changes in regulatory agency review procedures to accelerate clinical development. This paper provides a summary of the presentations given during the Coalition for Epidemic Preparedness Innovations (CEPI) workshop at the 2025 Society of Toxicology annual meeting. The workshop focused on several current aspects of toxicology studies for vaccines in the post-COVID era, including regulatory perspectives on vaccine nonclinical safety testing, and impact on development of lipid nanoparticles (LNPs), mRNA vaccines, and novel adjuvants. The conclusion from the workshop was that it is time for a review and update of vaccines guidance documents to incorporate learnings from the approximately last 35 years.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Gould S, Rohde CM, Destexhe E, et al. Summary of 2025 Society of Toxicology Workshop "Vaccine Toxicology in the Post-COVID Era". Vaccine. 2026. PMID: 42822179. doi:10.1016/j.vaccine.2026.129180

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。